FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017300912> ?p ?o ?g. }

• W2017300912 endingPage "367" @default.
• W2017300912 startingPage "361" @default.
• W2017300912 abstract "Background Active surveillance testing (AST) and decontamination strategies (DS) using a topical methicillin-resistant Staphylococcus aureus (MRSA) cleansing agent was introduced in July 2007 in a medical intensive care unit (MICU) and a surgical ICU (SICU) of a tertiary care hospital to reduce the incidence of MRSA infection. Methods Data on ICU admissions between July 1, 2007, and June 30, 2008, was analyzed. All subjects, excluding known MRSA status, had an ICU length of stay (LOS) of more than 24 hours and nasal swabs performed on ICU admission, every 7 days during the ICU stay, and on discharge. MICU and SICU specimens were sent for culture and in-house real-time polymerase chain reaction, respectively. MRSA-colonized (MRSAc) patients were subjected to contact isolation precautions and DS for 5 days or until ICU discharge. Data recorded included demographics, LOS, and antibiotic use. Results were analyzed using SPSS. Control charts were used to determine special cause variation. Results Of 653 eligible patients admitted to the ICU, 85 (13%) were determined to be MRSAc on ICU admission. A further 15% (52 of 351) were determined to be MRSAc during the ICU stay or at discharge. Thus, AST detected MRSA in at least 137 of the 653 patients (21.0%). In contrast, clinical cultures for MRSA were positive in only 12 patients (1.8%). Compared with noncolonized patients, MRSAc patients at any screening point had a longer pre-ICU LOS (P =.001), received more antibiotics (P = .004), and had a longer ICU LOS (P = .003). Compared with the preintervention period of July 2006 to June 2007, there was no significant reduction in mean MRSA infection incidence rate in both ICUs (3.8 to 3.0 per 1000 patient-days [P = .057] in the SICU and 1.4 to 1.7 per 1000 patient-days in the MICU) following intervention. Conclusions In ICUs, AST detected 11 times more MRSA than clinical cultures. The lack of reduction in MRSA infection rates in the ICUs does not negate the roles of AST and DS, but does argue for better study design and outcome measures like MRSA transmission incidence, which perhaps would have demonstrated a true benefit of AST and DS. Active surveillance testing (AST) and decontamination strategies (DS) using a topical methicillin-resistant Staphylococcus aureus (MRSA) cleansing agent was introduced in July 2007 in a medical intensive care unit (MICU) and a surgical ICU (SICU) of a tertiary care hospital to reduce the incidence of MRSA infection. Data on ICU admissions between July 1, 2007, and June 30, 2008, was analyzed. All subjects, excluding known MRSA status, had an ICU length of stay (LOS) of more than 24 hours and nasal swabs performed on ICU admission, every 7 days during the ICU stay, and on discharge. MICU and SICU specimens were sent for culture and in-house real-time polymerase chain reaction, respectively. MRSA-colonized (MRSAc) patients were subjected to contact isolation precautions and DS for 5 days or until ICU discharge. Data recorded included demographics, LOS, and antibiotic use. Results were analyzed using SPSS. Control charts were used to determine special cause variation. Of 653 eligible patients admitted to the ICU, 85 (13%) were determined to be MRSAc on ICU admission. A further 15% (52 of 351) were determined to be MRSAc during the ICU stay or at discharge. Thus, AST detected MRSA in at least 137 of the 653 patients (21.0%). In contrast, clinical cultures for MRSA were positive in only 12 patients (1.8%). Compared with noncolonized patients, MRSAc patients at any screening point had a longer pre-ICU LOS (P =.001), received more antibiotics (P = .004), and had a longer ICU LOS (P = .003). Compared with the preintervention period of July 2006 to June 2007, there was no significant reduction in mean MRSA infection incidence rate in both ICUs (3.8 to 3.0 per 1000 patient-days [P = .057] in the SICU and 1.4 to 1.7 per 1000 patient-days in the MICU) following intervention. In ICUs, AST detected 11 times more MRSA than clinical cultures. The lack of reduction in MRSA infection rates in the ICUs does not negate the roles of AST and DS, but does argue for better study design and outcome measures like MRSA transmission incidence, which perhaps would have demonstrated a true benefit of AST and DS." @default.
• W2017300912 created "2016-06-24" @default.
• W2017300912 creator A5004349354 @default.
• W2017300912 creator A5014043395 @default.
• W2017300912 creator A5019177579 @default.
• W2017300912 creator A5024618604 @default.
• W2017300912 creator A5033845978 @default.
• W2017300912 creator A5053709603 @default.
• W2017300912 creator A5065684984 @default.
• W2017300912 creator A5086009104 @default.
• W2017300912 date "2010-06-01" @default.
• W2017300912 modified "2023-10-14" @default.
• W2017300912 title "Active surveillance testing and decontamination strategies in intensive care units to reduce methicillin-resistant Staphylococcus aureus infections" @default.
• W2017300912 cites W1586159236 @default.
• W2017300912 cites W1988664990 @default.
• W2017300912 cites W2001280008 @default.
• W2017300912 cites W2012706218 @default.
• W2017300912 cites W2023218259 @default.
• W2017300912 cites W2028875480 @default.
• W2017300912 cites W2033146990 @default.
• W2017300912 cites W2033386465 @default.
• W2017300912 cites W2034674980 @default.
• W2017300912 cites W2036206262 @default.
• W2017300912 cites W2045860613 @default.
• W2017300912 cites W2053886251 @default.
• W2017300912 cites W2079509698 @default.
• W2017300912 cites W2108293734 @default.
• W2017300912 cites W2110769734 @default.
• W2017300912 cites W2114764103 @default.
• W2017300912 cites W2115044119 @default.
• W2017300912 cites W2121259468 @default.
• W2017300912 cites W2124502224 @default.
• W2017300912 cites W2127459993 @default.
• W2017300912 cites W2129065693 @default.
• W2017300912 cites W2130311744 @default.
• W2017300912 cites W2144719549 @default.
• W2017300912 cites W2155904369 @default.
• W2017300912 cites W2166776540 @default.
• W2017300912 cites W2199968683 @default.
• W2017300912 cites W2205919670 @default.
• W2017300912 cites W4241768922 @default.
• W2017300912 doi "https://doi.org/10.1016/j.ajic.2009.09.018" @default.
• W2017300912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20189267" @default.
• W2017300912 hasPublicationYear "2010" @default.
• W2017300912 type Work @default.
• W2017300912 sameAs 2017300912 @default.
• W2017300912 citedByCount "27" @default.
• W2017300912 countsByYear W20173009122012 @default.
• W2017300912 countsByYear W20173009122014 @default.
• W2017300912 countsByYear W20173009122015 @default.
• W2017300912 countsByYear W20173009122016 @default.
• W2017300912 countsByYear W20173009122017 @default.
• W2017300912 countsByYear W20173009122018 @default.
• W2017300912 countsByYear W20173009122020 @default.
• W2017300912 countsByYear W20173009122023 @default.
• W2017300912 crossrefType "journal-article" @default.
• W2017300912 hasAuthorship W2017300912A5004349354 @default.
• W2017300912 hasAuthorship W2017300912A5014043395 @default.
• W2017300912 hasAuthorship W2017300912A5019177579 @default.
• W2017300912 hasAuthorship W2017300912A5024618604 @default.
• W2017300912 hasAuthorship W2017300912A5033845978 @default.
• W2017300912 hasAuthorship W2017300912A5053709603 @default.
• W2017300912 hasAuthorship W2017300912A5065684984 @default.
• W2017300912 hasAuthorship W2017300912A5086009104 @default.
• W2017300912 hasConcept C120665830 @default.
• W2017300912 hasConcept C121332964 @default.
• W2017300912 hasConcept C126322002 @default.
• W2017300912 hasConcept C166888038 @default.
• W2017300912 hasConcept C177713679 @default.
• W2017300912 hasConcept C194828623 @default.
• W2017300912 hasConcept C2776376669 @default.
• W2017300912 hasConcept C2777052132 @default.
• W2017300912 hasConcept C2779489039 @default.
• W2017300912 hasConcept C2987404301 @default.
• W2017300912 hasConcept C501593827 @default.
• W2017300912 hasConcept C523546767 @default.
• W2017300912 hasConcept C54355233 @default.
• W2017300912 hasConcept C61511704 @default.
• W2017300912 hasConcept C71924100 @default.
• W2017300912 hasConcept C86803240 @default.
• W2017300912 hasConcept C89423630 @default.
• W2017300912 hasConceptScore W2017300912C120665830 @default.
• W2017300912 hasConceptScore W2017300912C121332964 @default.
• W2017300912 hasConceptScore W2017300912C126322002 @default.
• W2017300912 hasConceptScore W2017300912C166888038 @default.
• W2017300912 hasConceptScore W2017300912C177713679 @default.
• W2017300912 hasConceptScore W2017300912C194828623 @default.
• W2017300912 hasConceptScore W2017300912C2776376669 @default.
• W2017300912 hasConceptScore W2017300912C2777052132 @default.
• W2017300912 hasConceptScore W2017300912C2779489039 @default.
• W2017300912 hasConceptScore W2017300912C2987404301 @default.
• W2017300912 hasConceptScore W2017300912C501593827 @default.
• W2017300912 hasConceptScore W2017300912C523546767 @default.
• W2017300912 hasConceptScore W2017300912C54355233 @default.
• W2017300912 hasConceptScore W2017300912C61511704 @default.
• W2017300912 hasConceptScore W2017300912C71924100 @default.
• W2017300912 hasConceptScore W2017300912C86803240 @default.
• W2017300912 hasConceptScore W2017300912C89423630 @default.

• next